Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Kadcyla
Biotech
After Enhertu: The slow hunt for next-gen HER2 breast cancer drugs
From dual-payload ADCs to bispecifics and radioligands, drugmakers are hunting for answers either after Enhertu progression or to replace it.
Angus Liu
Oct 28, 2026 9:00am
BioNTech's ADC beats Roche’s Kadcyla in breast cancer phase 3
Sep 5, 2025 7:30am
Byondis ready to link up to bring Herceptin-booster to market
Jun 8, 2021 12:25pm
AstraZeneca, Daiichi's ADC keeps breast cancer at bay
Dec 11, 2019 8:00am
